We invest exclusively in founder-led biotechnology companies built and operated by physicians or scientists advancing clinically meaningful science. Our focus is human therapeutics grounded in clear biological mechanisms, supported by robust translational and early clinical data, and directed toward defined regulatory pathways.
We invest exclusively in founder-led biotechnology companies built and operated by physicians or scientists advancing clinically meaningful science. Our focus is human therapeutics grounded in clear biological mechanisms, supported by robust translational and early clinical data, and directed toward defined regulatory pathways.
We prefer assets that are Phase 2 or Phase 3 ready, where clinical risk is substantially reduced and value inflection is visible. On a selective, case-by-case basis, we will back Phase 1 programs where the mechanistic rationale, data package, and development strategy meet our underwriting standards.
We believe the most valuable biotech companies are created when the scientific originator remains central to strategy, capital allocation, and clinical execution. If you are a scientific founder developing differentiated therapeutic science with a defined path to clinical inflection, we want to hear from you.
Our underwriting framework is built around five interlocking criteria that govern every investment decision. Each dimension must be satisfied independently.
We back physician and scientist founders with demonstrated authority in their field and the ability to defend their mechanistic rationale rigorously.
Programs must demonstrate clear mechanistic differentiation with intellectual property strategically aligned with development objectives.
Each company must present a rational first indication and a well-defined proof-of-concept study design with identifiable value inflection points.
Every financing round must be tied to a specific, value-creating milestone. We avoid unfocused platform expansion without defined priorities.
We seek founder-led governance structures and transparent communication. Long-term value creation must supersede short-term valuation engineering. We are partners in the scientific mission, not passive capital allocators.
Our portfolio reflects concentrated conviction. We maintain a focused number of investments and engage actively at the scientific and clinical strategy level. We prioritize substance over scale and conviction over volume.
Scientific originators central to strategy, capital allocation, and clinical execution across all portfolio companies.
Therapeutically rigorous science with compelling preclinical validation and clearly articulated mechanism of action.
Each portfolio company demonstrates a clear clinical development pathway with identifiable inflection milestones.
Jurisdictional regulatory understanding and defined approval strategies form the foundation of every investment thesis.
We engage deeply in clinical planning, regulatory positioning, and milestone design — not as financial intermediaries, but as scientific collaborators committed to maximizing probability of success.
Our investment partners bring scientific, clinical development, and regulatory expertise. We operate as scientific collaborators rather than purely financial investors — deeply engaged at every critical inflection point.
Deep domain knowledge across therapeutic areas, enabling rigorous evaluation of mechanistic rationale and preclinical data packages.
Hands-on engagement in trial design, endpoint selection, and milestone structuring to maximise the probability of clinical success.
Nuanced understanding of global regulatory pathways, enabling portfolio companies to navigate approval strategies with precision.
Our advisory network includes key opinion leaders, translational scientists, and clinical development strategists who support portfolio companies at critical inflection points. This network provides access to deep domain expertise that complements our internal capabilities, ensuring portfolio founders have the scientific and strategic support necessary to execute on their development plans.
If you're a scientific founder with differentiated therapeutic science and a defined path to clinical inflection, reach out.
Submissions should include a concise overview of mechanism of action, preclinical data summary, intellectual property status, proposed first clinical indication, and defined clinical inflection milestone. We review all opportunities that meet our founder and scientific criteria.
Submit Your ProgramWe maintain a focused, thesis-driven strategy centred on selective backing of MD or PhD-led biotechnology companies. For institutional inquiries, please request our fund overview and diligence materials.
Request MaterialsFor corporate or media matters, please contact the fund directly. We endeavour to respond to all substantive inquiries within five business days.
Contact the Fund